keyword
MENU ▼
Read by QxMD icon Read
search

alopecia universalis

keyword
https://www.readbyqxmd.com/read/28635319/a-case-of-topical-ruxolitinib-treatment-failure-in-alopecia-areata
#1
Maya Deeb, Renée A Beach
Alopecia areata (AA) is an autoimmune-mediated, nonscarring form of hair loss. Despite its prevalence, current management options are limited, especially when the disease has progressed to alopecia totalis (AT) or alopecia universalis (AU). Recent evidence that janus kinase (JAK) signaling contributes to AA pathogenesis prompted the investigation of JAK inhibitors such as tofacitinib and ruxolitinib as possible oral treatments. However, the potential for significant adverse effects with systemic JAK inhibition makes local administration a more attractive option...
June 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28632888/excellent-response-to-tofacitinib-in-a-patient-with-alopecia-universalis
#2
Funda Erduran, Esra Adışen, Ahmet Burhan Aksakal
EAlopecia universalis (AU) is generally considered a variant of alopecia areata (AA), in which the treatment options seldom provide satisfactory results. However, successful treatment of several cases of AA and its variants with oral Janus kinase (JAK) inhibitors have been reported recently. Here we report a 23-year-old female patient with AU successfully treated with tofacitinib, a selective JAK-3 inhibitor. The initial tofacitinib dose was 5 mg twice daily. After 2 months of treatment, partial hair regrowth was seen on the scalp and eyebrows...
June 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28627278/methotrexate-for-the-treatment-of-pediatric-alopecia-areata
#3
Erin T Landis, Rita O Pichardo-Geisinger
Alopecia areata is a form of nonscarring hair loss which occurs in pediatric and adult patients, with presentation varying from round or ovoid patches of alopecia to alopecia totalis or universalis. While frustrating for patients, it can also be frustrating for clinicians to treat, as there is no definitive treatment. Dermatologists are very familiar with the use of methotrexate for psoriasis and other inflammatory skin diseases, and this medication is generally well tolerated in children. This study present a case series reviewing the efficacy of methotrexate in our pediatric patients with alopecia areata, making use of a retrospective chart review design from 2011-2016...
June 19, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28536724/successful-hair-regrowth-in-a-korean-patient-with-alopecia-universalis-following-tofacitinib-treatment
#4
Bo Young Kim, Hyun-Sook Kim
No abstract text is available yet for this article.
May 2017: Singapore Medical Journal
https://www.readbyqxmd.com/read/28515996/dermoscopy-of-alopecia-areata-a-retrospective-analysis
#5
Abhijeet K Jha, Uday K Udayan, P K Roy, Amar K J Amar, R K P Chaudhary
BACKGROUND: Dermoscopy devices can overcome the refractive properties of stratum corneum by interface medium or cross polarization such that the lesion can be easily seen. AIM: To examine the dermoscopic feature in alopecia areata and correlate the severity of disease with dermoscopic features. MATERIALS AND METHODS: Retrospective analysis of 72 patients suffering from alopecia areata (AA), irrespective of age and sex, who visited the dermatology outpatient department of a tertiary care center in Eastern India was carried out...
April 2017: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/28492603/recovery-of-hair-in-the-psoriatic-plaques-of-a-patient-with-coexistent-alopecia-universalis
#6
Christine Anastasiou, Carolyn Goh, Vanessa Holland
No abstract text is available yet for this article.
April 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28378336/review-of-treatment-for-alopecia-totalis-and-alopecia-universalis
#7
REVIEW
Sama Kassira, Dorota Z Korta, Lance W Chapman, Francis Dann
Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. This review focuses on the evidence for current treatment options for AT and AU. The PubMed database was searched from January 1, 2000, to September 1, 2016, for clinical trials, retrospective studies, and case reports of treatments for AT and AU...
April 5, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28349112/treatment-of-alopecia-universalis-with-oral-alitretinoin-a-case-report
#8
Pierre-Olivier Grenier, Hélène Veillette
No abstract text is available yet for this article.
March 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28329493/ichthyosis-follicularis-with-alopecia-and-photophobia-syndrome-ifap-a-case-report
#9
Bruno Ferrari, Lucila Morita, Keith Choate, Rong-Hua Hu
IFAP syndrome is a rare autosomal recessive X-linked disease characterized by the triad of alopecia universalis, severe photophobia, and follicular ichthyosis. It is caused by loss of function of the gene MBTPS2. Its severity varies and there are only a few reports in the literature. We present a patient with characteristic clinical features and a mutation not previously reported.
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28325392/experience-with-oral-tofacitinib-in-8-adolescent-patients-with-alopecia-universalis
#10
Leslie Castelo-Soccio
No abstract text is available yet for this article.
April 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28322434/two-cases-of-alopecia-areata-treated-with-ruxolitinib-a%C3%A2-discussion-of-ideal-dosing-and-laboratory-monitoring
#11
Amy Vandiver, Nicholas Girardi, Jihad Alhariri, Luis A Garza
BACKGROUND: Alopecia areata is a relatively common condition affecting patients seen in community dermatology clinics. A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting. METHODS: A patient with chronic alopecia areata and a patient with acute onset alopecia universalis were treated with oral ruxolitinib for over a year...
March 21, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28140540/sequential-high-and-low-dose-systemic-corticosteroid-therapy-for-severe-childhood-alopecia-areata
#12
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
BACKGROUND: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Following initial pulse therapy, continuation of corticosteroid therapy at a dose below the Cushing threshold might be able to suppress disease activity without causing severe side effects...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28140533/kombinierte-hoch-niedrig-dosis-therapie-mit-systemischen-glukokor-tikoiden-bei-schweren-verlaufsformen-der-alopecia-areata-im-kindesalter
#13
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
HINTERGRUND: Schwere Verlaufsformen der Alopecia areata (AA) im Kindesalter sind aufgrund limitierter Optionen therapeutisch herausfordernd. Systemische, hochdosierte Glukokortikoide weisen die schnellste Ansprechrate auf, nach dem Absetzen kommt es allerdings zu Rezidiven. Eine längerfristige Hochdosis-Anwendung ist aufgrund der zu erwartenden Nebenwirkungen nicht empfehlenswert. Eine dauerhafte Steroiderhaltungstherapie unterhalb der Cushing-Schwellen-Dosis nach Bolustherapie könnte die Krankheitsaktivität ohne Nebenwirkungen längerfristig unterdrücken...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28101018/remarkable-improvement-of-nail-changes-in-alopecia-areata-universalis-with-10-months-of-treatment-with-tofacitinib-a-case-report
#14
Sineida Berbert Ferreira, Morton Scheinberg, Denise Steiner, Tatiana Steiner, Gustavo Longhi Bedin, Rachel Berbert Ferreira
Alopecia areata (AA) is a chronic, autoimmune disease. The main symptom is massive hair loss, localized or diffuse, in the scalp and the whole body. However, nails may also be involved, and brittleness, fragility and pitting can be signs of nail dystrophy in AA patients. Here, we report the case of a male patient with AA refractory to various treatments, including oral, topical and intralesional corticosteroids, immunosuppressants, cyclosporin and PUVA (oxoralen plus ultraviolet light), all interrupted due to side effects...
September 2016: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28077132/foxn1-deficient-nude-severe-combined-immunodeficiency
#15
REVIEW
Ioanna A Rota, Fatima Dhalla
Nude severe combined immunodeficiency is a rare inherited disease caused by autosomal recessive loss-of-function mutations in FOXN1. This gene encodes a transcription factor essential for the development of the thymus, the primary lymphoid organ that supports T-cell development and selection. To date nine cases have been reported presenting with the clinical triad of absent thymus resulting in severe T-cell immunodeficiency, congenital alopecia universalis and nail dystrophy. Diagnosis relies on testing for FOXN1 mutations, which allows genetic counselling and guides therapeutic management...
January 11, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28074525/efficacy-of-superficial-cryotherapy-on-the-eyebrows-of-patients-with-alopecia-universalis-also-treated-with-contact-immunotherapy-on-the-scalp-a-prospective-split-face-comparative-study
#16
Sung Jay Choe, Won-Soo Lee
BACKGROUND: Few treatment modalities are available for treating alopecia areata (AA) of the eyebrow. Due to the anatomical proximity of the eyebrows to the eyes, safety issues and side effects should always be taken into consideration when choosing the treatment modality. This study was designed to examine the efficacy of superficial cryotherapy on patients with AA of the eyebrow. METHODS: Superficial cryotherapy was performed every other week on the right eyebrow (SC-treated) in a total of 20 patients who had been previously treated with diphenylcyclopropenone (DPCP) immunotherapy on the scalp...
February 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/27943234/immune-related-alopecia-areata-and-universalis-in-cancer-patients-receiving-immune-checkpoint-inhibitors
#17
A Zarbo, V R Belum, V Sibaud, S Oudard, M A Postow, J J Hsieh, R J Motzer, K J Busam, M E Lacouture
Cytotoxic T-lymphocyte-associated protein-4, programmed cell death protein and programmed cell death protein ligand 1 monoclonal antibodies (immune checkpoint inhibitors), are used to treat various malignancies. Their mechanism of action involves the inhibition of negative regulators of immune activation, resulting in immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatological events. Dermatological irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea and the exacerbation of psoriasis...
June 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/27843927/alopecia-areata-as-a-manifestation-of-systemic-lymphoma-report-of-two-cases
#18
Yuval Ramot, Alexander Gural, Abraham Zlotogorski
Alopecia areata is a common autoimmune disorder leading to hair loss. It usually affects individuals under the age of 40, and first appearance in older subjects is considered uncommon. Here, we report 2 cases of rapidly progressing alopecia areata, which appeared for the first time in adults. Patient 1 had alopecia universalis, which preceded the identification of hepatosplenic T-cell lymphoma, a rare form of lymphoma. Patient 2 suffered from the ophiasis type of alopecia areata, presenting for the first time following chemotherapy for non-Hodgkin B-cell lymphoma...
September 2016: Skin Appendage Disorders
https://www.readbyqxmd.com/read/27816293/tofacitinib-for-the-treatment-of-severe-alopecia-areata-and-variants-a-study-of-90-patients
#19
Lucy Y Liu, Brittany G Craiglow, Feng Dai, Brett A King
BACKGROUND: Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. OBJECTIVE: We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time. METHODS: This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment...
January 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27741937/alopecia-universalis-as-a-side-effect-of-pegylated-interferon-%C3%AE-ribavirin-combination-therapy-for-hepatitis-c-a-rare-case-report
#20
Poonam Verma, Surabhi Dayal, V K Jain, Ashish Amrani
Pegylated interferon α and ribavirin therapy is associated with increased incidence of various systemic and cutaneous side effects. Among the side effects of this therapy, alopecia universalis is a rarely reported side effect which causes significant cosmetic concern to the patient. We report a rare case of alopecia universalis which developed eight weeks after discontinuation of this antiviral combination therapy. This gains importance because it is essential to sensitize the treating gastroenterologist and the dermatologist regarding this rare side effect...
October 14, 2016: Journal of Chemotherapy
keyword
keyword
93734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"